The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …

During the past decade, immunotherapies have made a major impact on the treatment of
diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and …

Background & Aims Immune checkpoint inhibitors (ICIs) have transformed the treatment
landscape for oncology, leading to durable remissions in a subset of patients, but also a …

Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …